BioSpace News Archive

When a group of our neurons get activated by thinking hard about a math problem or the vibrant colors of an exotic flower, within a single second blood flow to those brain cells increases a bit.

Acquired assets from NCARDIA AG include IP portfolio, IPSC-based cellular products and an experienced stem cell biology team

One problem facing researchers in Alzheimer’s disease is the lack of really good diagnostic tests. Earlier this year, Bill Gates, Jeff Bezos and MacKenzie Bezos teamed to donate over $20 million to the Diagnostics Accelerator, part of the Alzheimer’s Drug Discovery Foundation (ADDF).

Although the American public, Congress and the Trump administration have pressed for meaningful legislation over drug pricing, time is running out this year.

The M&A moves are expected to increase the oncology pipelines of both companies.

Acacia Pharma Group plc welcomes an editorial published in the leading peer-reviewed journal Anesthesia & Analgesia, accompanying the print publication of results from its positive Phase 3 clinical trial of BARHEMSYS® as treatment of post-operative nausea & vomiting in patients who had not received prior prophylaxis*.

Board appointment will help guide target identification and drug discovery

Todos Medical Ltd. announced positive results from a pre-specified interim analysis of 20 subjects from an ongoing 40-subject outpatient study evaluating the relationship between LymPro Test™ scores with amyloid PET imaging scores.

The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to AstraZeneca over its supplemental New Drug Application (sNDA) for Farxiga (dapagliflozin) as an adjunct treatment to insulin for type 1 diabetes (T1D) when insulin alone doesn’t keep blood sugar levels under control.

Galapagos will receive $3.95 billion in upfront cash, as well as a $1.1 billion equity investment from Gilead as the California company gains access to numerous compounds in Galapagos’ pipeline.